GLP-1 Medications May Improve Long-Term Health for People with Peripheral Artery Disease

GLP-1s tied to better outcomes for diabetes, peripheral artery disease

A new study suggests GLP-1 medications, such as semaglutide, were associated with better overall outcomes in people with type 2 diabetes and peripheral artery disease (PAD), particularly those at highest risk of amputation.

GLP-1 medications may improve long-term health for people with peripheral artery disease

GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease), according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

GLP-1 medications found to reduce deaths, amputations and hospitalisations in PAD and type 2 diabetes patients

Aravinda Nanjundappa. Copyright Transcatheter Therapeutics (TCT) Professional Studio San Francisco GLP-1 receptor agonists (GLP-1 RA) medications can reduce the number of deaths, amputations and hospitalisations among patients with peripheral arterial disease (PAD) and type 2 diabetes, according to new, independent research published in the Journal of the American Heart Association (JAHA). “Because GLP-1 RAs show significant benefits, especially…

Can GLP-1 Medications Enhance Health Outcomes in Individuals with Type 2

In a groundbreaking advancement for the intersection of endocrinology and vascular medicine, recent research has illuminated the multifaceted benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in improving long-term outcomes for patients grappling with both Type 2 diabetes and peripheral artery disease (PAD). Published in the Journal of the American Heart Association, this new evidence underscores the significant potential of GLP-…

Can GLP-1 Medications Improve Health in People With Type 2 Diabetes and PAD?

Open the article to view the coverage from NewMediaWire